![Torsten Malmström](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Torsten Malmström
Technik-/Wissenschafts-/F&E-Leiter bei CAMURUS AB
Vermögen: 2 Mio $ am 31.07.2024
Profil
Torsten Malmström is currently the Chief Technical Officer at Camurus AB.
Previously, he worked as the Director-Pharmaceutical Development at Zealand Pharma A, the Development Director at PolyPeptide Laboratories (Sweden) AB, and the Team Manager at AstraZeneca AB.
Dr. Malmström holds a doctorate degree from the University of Lund.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
CAMURUS AB
0,06% | 17.07.2024 | 35 363 ( 0,06% ) | 2 Mio $ | 31.07.2024 |
Aktive Positionen von Torsten Malmström
| Unternehmen | Position | Beginn |
|---|---|---|
| CAMURUS AB | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2013 |
Ehemalige bekannte Positionen von Torsten Malmström
| Unternehmen | Position | Ende |
|---|---|---|
| ZEALAND PHARMA A/S | Corporate Officer/Principal | - |
AstraZeneca AB
 AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Corporate Officer/Principal | - |
PolyPeptide Laboratories (Sweden) AB
 PolyPeptide Laboratories (Sweden) AB BiotechnologyHealth Technology PolyPeptide Laboratories (Sweden) AB specializes in the production of proprietary peptides. The firm manufactures polypeptide, custom peptide Synthesis, peptide synthesis, and generic peptide. Its peptides products are part of several different pharmaceutical products. The company was founded in 1996 and is headquartered in Malmo, Sweden. | Corporate Officer/Principal | - |
Ausbildung von Torsten Malmström
| University of Lund | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| CAMURUS AB | Health Technology |
| ZEALAND PHARMA A/S | Health Technology |
| Private Unternehmen | 2 |
|---|---|
PolyPeptide Laboratories (Sweden) AB
PolyPeptide Laboratories (Sweden) AB BiotechnologyHealth Technology PolyPeptide Laboratories (Sweden) AB specializes in the production of proprietary peptides. The firm manufactures polypeptide, custom peptide Synthesis, peptide synthesis, and generic peptide. Its peptides products are part of several different pharmaceutical products. The company was founded in 1996 and is headquartered in Malmo, Sweden. | Health Technology |
AstraZeneca AB
AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Commercial Services |
